Infectious Disease

Akston commences dosing in Phase II trial of Covid-19 vaccine

Akston Biosciences has initiated dosing of the first subjects in a Phase II open-label trial of AKS-452, its protein subunit Covid-19 vaccine candidate.

NIH study completes subject enrolment for Brii Biosciences’ Covid-19 antibodies

Brii Biosciences has announced that ACTIV-2 clinical trial of the National Institutes of Health (NIH) in the US closed enrolment for the Phase III part that will evaluate BRII-196 plus BRII-198 for Covid-19 treatment.

Dr. Reddy’s begins pilot of Russia’s Sputnik V vaccine in India

Dr. Reddy’s Laboratories has started a limited pilot of the Sputnik V Covid-19 vaccine, developed by Russian scientists, in India following regulatory authorisation from the Central Drugs Laboratory.

US FDA approves emergency use of Pfizer-BioNTech Covid-19 vaccine in adolescents

The US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) for Pfizer and BioNTech’s Covid-19 vaccine to include adolescents aged 12 to 15 years.

India’s DCGI allows use of oxygen dependence-lowering Covid-19 drug

The Drugs Controller General of India (DCGI) has granted emergency use authorisation for a new drug, 2-deoxy-D-glucose (2-DG), as adjunct therapy that can help lower supplemental oxygen dependence in moderate to severe Covid-19 patients.

Pfizer-BioNTech Covid-19 vaccine gets Canada approval for adolescents

Pfizer Canada and BioNTech have received Interim Order authorisation from Health Canada for the use of their Covid-19 vaccine in adolescents aged 12 to 15 years.

Johnson & Johnson to resume Covid-19 vaccine roll-out in Europe after EMA review

Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile being positive.

Airway Therapeutics’ IND application for AT-100 gets FDA acceptance to treat Covid-19

The US Food and Drug Administration (FDA) has approved Investigational New Drug (IND) application submitted by Airway Therapeutics to develop AT-100 (rhSP-D) for treating patients with Covid-19.

Anixa and OntoChem enter next stage of Covid-19 anti-viral therapy development

Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy for Covid-19.